Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Farnesyltransferase inhibitor
BML-G242-0005 5 mg 396.00 USD
Do you need bulk/larger quantities?
Ras farnesyltransferase inhibitor. Induces tumor regression in transgenic mice with multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Induces p21 expression and arrests cells at G1. Causes enhanced mitotic sensitivity to taxol.

Product Details

Purity:≥98% (TLC)
Appearance:White solid.
Solubility:Soluble in DMSO, water, or acetonitrile.
Shipping:Ambient Temperature
Long Term Storage:-20°C
Use/Stability:Store solutions at -20°C for up to 3 months.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK: Y. Dai, et al.; Blood 105, 1706 (2005), Abstract;
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras: M.M. Feldkamp, et al.; Int. J. Cancer 81, 118 (1999), Abstract;
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells: L. Sepp-Lorenzino & N. Rosen; J. Biol. Chem. 273, 20243 (1998), Abstract;
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis: R.E. Barrington, et al.; Mol. Cell Biol. 18, 85 (1998), Abstract;
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones: M.M. Moasser, et al.; PNAS U.S.A. 95, 1369 (1998), Abstract;